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Abstract Introduction: Neuronal p3-Alcb peptides are generated from the precursor protein Alcadein b
(Alcb) through cleavage by a- and g-secretases of the amyloid b (Ab) protein precursor (APP). To
reveal whether p3-Alcb is involved in Alzheimer’s disease (AD) contributes for the development
of novel therapy and/or drug targets.
Methods: We developed new sandwich enzyme-linked immunosorbent assay (sELISA) systems to
quantitate levels of p3-Alcb in the cerebrospinal fluid (CSF).
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Results: In monkeys, CSF p3-Alcb decreases with age, and the aging is also accompanied by
decreased brain expression of Alcb. In humans, CSF p3-Alcb levels decrease to a greater extent
in those with AD than in age-matched controls. Subjects carrying presenilin gene mutations
show a significantly lower CSF p3-Alcb level. A cell study with an inverse modulator of g-sec-
retase remarkably reduces the generation of p3-Alcb37 while increasing the production of
Ab42.
Discussion: Aging decreases the generation of p3-Alcb, and further significant decrease of p3-Alcb
caused by aberrant g-secretase activity may accelerate pathogenesis in AD.
 2019 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).
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1. Introduction
The Alcadein family of proteins (Alcs) comprises three
members: Alcadein a (Alca), Alcadein b (Alcb), and Alca-
dein g (Alcg), which are type I transmembrane proteins, en-
coded by their respective independent genes. They are also
termed calsyntenin (Clstns) exclusively expressed in
neuronal tissues [1,2] and serve a variety of functions:
Ca21-binding [3], cargo receptors for kinesin-1 [4–9],
regulators of secretory pathways [10–12], and
synaptogenesis [13–15].
Some type I transmembrane proteins are subject to regu-
lated intramembrane proteolysis (RIP) after a primary cleav-
age in the juxtamembrane region [16]. The amyloid b (Ab)
protein precursor (APP) is cleaved by either a-secretase
(ADAM10/17) or b-secretase (BACE1), and the resulting
carboxyl-terminal fragments (CTFs) are further cleaved by
g-secretase in the membrane, resulting in secretion of either
p3 or Ab peptides and release of the APP intracellular
domain (AICD) into the cytoplasm [17]. Ab forms soluble
oligomers that influence synaptic plasticity or exert neuro-
toxicity [18], and AICD may regulate nuclear functions
[19]. APP metabolism is intimately involved in the patho-
genesis of Alzheimer’s disease (AD). Alcs are also subject
to proteolytic cleavage by a combination of a- and g-secre-
tases, yielding secreted p3-Alc and the intracellular domain
fragment Alc ICD [11,20,21]. As with Ab, secreted p3-Alc
is detectable in cerebrospinal fluid (CSF) and later in blood.
In p3-Alcb, the major p3-Alcb37 and minor p3-Alcb40 mol-
ecules are present in CSF [21,22]. These are generated by an
alternative g-secretase cleavage of Alcb CTF. Thus, p3-
Alcb40 possesses three more C-terminal amino acids than
p3-Alcb37 [21].
Changes in the activity of g-secretase can alter the
final cleavage site of Alcs (i.e. the g-site) as has been
observed for the APP [21,23]. This alteration is detect-
able as an endophenotype of p3-Alca with C-terminal
variants in patients with AD [22] and in cells treated
with compounds that modulate g-secretase activity
[24,25]. These lines of evidence suggest that the function
and metabolism of Alcs are also closely involved in AD
pathobiology. In this study, we validated new specific
sandwich enzyme-linked immunosorbent assay (sELISA)
systems to specifically quantify p3-Alcb37 and p3-
Alcb40 and quantified these peptides in human and mon-
key CSF, as investigated for p3-Alca in blood and CSF
of patients with AD [26–28]. The results may provide
important insight into the alteration of p3-Alcb levels
in AD pathogenesis.
2. Materials and methods
2.1. Antibodies, the ELISA system, and synthetic peptides
Human p3-Alcb37 and p3-Alcb40 peptides include the
sequence from Val813 to Thr849 and to Ilu852 of Alcb,
respectively [21]. The polyclonal rabbit pan-p3-Alcb anti-
body #826 was raised to Cys plus the N-terminal sequence
betweenVal813 andHis821 of p3-Alcb. This antibody reacts
to all p3-Alcb species, but not p3-Alca and p3-Alcg peptides.
In sELISA, Fab’ fragments of affinity-purified IgG of #826
were conjugated with horseradish peroxidase and used to
detect the captured p3-Alcb with tetramethylbenzidine
colorimetrically at OD450 [27].
The polyclonal rabbit antibody was raised against an an-
tigen peptide composed of Cys plus the sequence between
positions 841and 849, and the monoclonal mouse antibody
was raised against a peptide composed of Cys plus the
sequence between positions 844 and 853. One antibody
showing specific reactivity to p3-Alcb37 was designed 37-
specific, wheas the another antibody showing specificity to
p3-Alcb40 was designed 40-specific. These antibodies
were affinity purified with respective antigen columns.
Ab40 and Ab42 were quantified with a commercial
sELISA (IBL, Fujioka, Japan, for nonhuman materials
and cohort 2). Cohort 3 was analyzed for Ab42, tau
and/or ptau181 twice with different procedures, which
were designed as cohort 3a and 3b. Ab42 in cohort 3a
was quantified with sELISA (Wako Chemical Co.,
Osaka, Japan). Total tau and ptau181 in cohorts 2 and
3a were quantified with an Inotest ELISA kit (Innoge-
netics, N.V. Ghent, Belgium). Ab42, total tau, and
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ptau181 in cohort 1 and cohort 3b were quantified with
INNO-BIA AlzBio3 xMAP assay (Innogenetics). The
p3-Alcb37, p3-Alcb40, and Ab42 peptides were synthe-
sized in the Saito Research Center of Peptide Institute
(Osaka, Japan).
2.2. Cohort information
Data for cohorts are shown in Table 1. AD was clin-
ically diagnosed based on two major criteria: Diag-
nostic and Statistical Manual of Mental Disorders, 5th
Edition: DSM-V and National Institute of Neurological
and Communicational Disorders and Stroke–Alzheim-
er’s Disease and Related Disorders Association
(NINCDS-ADRDA). CSF was obtained from the auto-
somal dominantly inherited patients with AD and their
families and participants from the Australian Imaging,
Biomarker & Lifestyle Study of Aging (AIBL) cohort.
Informed consent for the use of all human CSF was
obtained and approved by the appropriate ethical
boards at each respective institution, hospital and/or
university (Niigata University, Higashi Matsudo Munic-
ipal Hospital, Hokkaido University, Edith Cowan Uni-
versity, Macquarie University, the University of
Melbourne, Austin Health, and National Aging
Research Institute).
2.3. Animals
All animal studies were conducted in compliance with
the guidelines of the Animal Studies Committee of Hok-
kaido University, the National Center for Geriatrics and
Gerontology, the National Institutes of Biomedical Inno-
vation, Health and Nutrition (NIBIOHN), and Shiga Uni-
versity of Medical Science. CSF samples of cynomolgus
monkeys (Macaca fascicularis) were obtained from the
National Center for Geriatrics and Gerontology and the
National Institute of Biomedical Innovation. Brain sam-
ples were obtained from the Tsukuba Primate Research
Center (TPRC), NIBIOHN, Japan. All monkeys were
bred and maintained in an air-conditioned room at the
TPRC with controlled illumination (12 h light/12 h
dark), temperature (23–27C), humidity (50–70%), and
ventilation (12 air changes/h). The maintenance and
care of animals were performed in accordance with the
rules for animal care of the TPRC at NIBIOHN for the
care, use, and biohazard countermeasure of laboratory
animals. This study was carried out in strict accordance
with the rules for animal care and management of the
TPRC [29], the Guiding Principles for Animal Experi-
ments Using Nonhuman Primates formulated by the Pri-
mate Society of Japan [30], and the Institute for
Laboratory Animal Research Guide for Care and Use of
Laboratory Animals. The research protocol was approved
by the Animal Care and Use Committee of NIBIOHN. In
the present study, the animals used in this study either
died of natural causes or were euthanized when they
reached endpoints determined as poor prognosis. For
euthanasia, the monkeys were deeply anesthetized with
a lethal dose of pentobarbital, and all efforts were made
to minimize suffering.
2.4. Cell culture, transfection of plasmids into cells, and
Aftin-5 treatment of cells
HEK293 cells were cultured in DMEM containing 5%
(v/v) fetal bovine serum (MP Biomedicals, Solon, OH,
USA). The cDNAs, pcDNA3.1-Alcadein b CTF, and
pcDNA3.1-APP C99 [23] were transiently transfected to
HEK293 cells with Lipofectamine 2000 (Invitrogen, Carls-
bad, CA, USA) and treated with or without an indicated
amount of Aftin-5 (AdipoGen, Liestal, Switzerland) for
24 h. The secreted p3-Alcb and Ab were recovered from
the cultured medium, and the amounts were quantified by
sELISA.
2.5. Immunoblotting
The brain was dissected from the indicated-year-old
monkeys [31] and analyzed for Alcb, APP, and flotillin
expression. The lysates of the cerebral cortex of monkeys
were analyzed as previously described by immunoblotting
with anti–Alcb-specific UT99 [20], anti-APP G369
[32,33], and anti–flotillin-1 (BD Bioscience) antibodies.
The levels of Alcb and the APP were quantified with
LAS-4000 mini (Fujifilm) and normalized against the corre-
sponding levels of flotillin-1.
3. Results
3.1. Development and characterization of ELISA systems
allowing the quantification of p3-Alcb37 and p3-Alcb40
The C-terminal end-specific antibodies 37-specific and
40-specific were shown to react with the respective
Table 1
Subject information of three independent cohorts
Number Female (%)
Age
(Mean 6 S.E.)
MMSE
(Mean 6 S.E.)
Cohort 1: Australia
Control 59 54.2 72.6 6 0.80 28.9 6 0.13
MCI 11 45.5 77.7 6 2.83 26.4 6 0.95
AD 11 54.5 75.1 6 1.78 19.8 6 1.26
Cohort 2: Japan-1
Control 14 35.7 75.9 6 1.64 28.0 6 0.469
MCI 25 48.0 78.0 6 1.46 21.7 6 0.681
AD 20 70.0 76.0 6 1.78 15.4 6 1.81
Cohort 3: Japan-2
Control 44 50.0 69.8 6 1.53 -
MCI 8 62.5 67.1 6 3.06 27.0 6 0.463
AD 45 48.9 68.3 6 1.53 17.0 6 0.925
Cohort 1 indicates Australian subjects, whereas Cohort 2 and Cohort 3
indicate Japanese subjects.
Abbreviations: MMSE, Mini-Mental State Examination; AD, Alzheim-
er’s disease; MCI, mild cognitive impairment; S.E., standard error.
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synthetic p3-Alcb37 and p3-Alcb40 peptides and did not
show any cross-reactivity (Fig. 1A), thus allowing us to
use these as antibodies to capture p3-Alcb37 and p3-
Alcb40 specifically.
The pan p3-Alcb antibody #826 recognizes both p3-
Alcb37 and p3-Alcb40 (data not shown). Thus, one sE-
LISA used a combination of 37-specific and #826 to detect
p3-Alcb37, whereas the other sELISA used the combina-
tion of 40-specific and #826 to detect p3-Alcb40. The spec-
ificity and the sensitivity of both sELISA are shown in
Fig. 1B. The sensitivity of both sELISA systems was
high enough to allow the quantification of p3-Alcb37 and
p3-Alcb40 levels in CSF, amounts which could be esti-
mated with an immunoprecipitation TOF-MS analysis
[21]. Both sELISA detected at least 7.8 pg/mL of p3-
Alcb37 and p3-Alcb40 (Fig. 1C).
3.2. Age-dependent decrease in p3-Alcb levels in CSF of
cynomolgus monkeys
We examined the levels of p3-Alcb in the CSF of various
aged cynomolgus monkeys along with the levels of Ab
(Fig. 2). The levels of p3-Alcb37 were comparable with
those of Ab40, being approximately in the 2000-10,000
pg/ml range in CSF, whereas p3-Alcb40 levels were similar
to Ab42 levels, in the range of 300-1500 pg/ml. Both p3-
Alcb37 and p3-Alcb40 levels decreased significantly in an
age-dependent manner (Fig. 2A). Ab40 and Ab42 levels
also decreased age-dependently in monkey CSF, although
the decrease in Ab42 was not statistically significant
(Fig. 2B). This decrease in CSF Ab levels in aged monkeys
may be due to aggregation and precipitation of Ab in the
brain, similar to that seen in elderly human subjects, because
A
B
C
Fig. 1. Amino acid sequence of p3-Alcb and specificity of the sELISA. (A) Antigen sequences on p3-Alcb. p3-Alcb37 includes the sequence from Val813 to
Thr849 and p3-Alcb40 includes the sequence from Val813 to Ile852. Numbers indicate amino acid position in human Alcb. Letters with a broken underline
indicate the putative transmembrane (TM) region, as suggested by Swiss-Prot. Double-lined letters alongside the sequence indicate antigen peptide sequences.
Antigen sequences were follows: antibody #826, Val813-His821; anti–p3-Alcb37, Asn841-Thr849; anti–p3-Alcb40, Leu844-Ile853. (B) Specific reactivity and
sensitivity of sELISA against p3-Alcb37 and p3-Alcb40. Left panel indicates reactivity of the p3-Alcb37-specific sELISA system, consisting of the #826 and
37-specific antibodies, and the right panel indicates the reactivity of the p3-Alcb40-specific sELISA system, consisting of the #826 and 40-specific antibodies.
The indicated amounts of synthetic p3-Alcb37 (open circle) and p3-Alcb40 (closed squire) were dissolved in PBS containing 1% bovine serum albumin and
0.05% Tween-20, and then subjected to assay with the corresponding sELISA system. The reaction was detected colorimetrically by monitoring absorption at
OD450 as described in Materials and methods. (C) Specific reactivity and sensitivity of sELISA against lower range of p3-Alcb37 and p3-Alcb40. Reactivity to
lower ranges of peptide concentration in panel B was shown. Abbreviations: sELISA, sandwich enzyme-linked immunosorbent assay; Alcb, Alcadein b; PBS,
phosphate buffered saline.
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Ab sequence of cynomolgus monkeys is identical to that of
humans. Consistent with this, the monkeys exhibit AD-
associated pathologies such as amyloid plaques around
25 years of age [31,34].
3.3. Age-dependent decrease of Alcb expression in the
brain of monkeys
Regardless of the non–aggregation-prone properties of
p3-Alcb peptides, p3-Alcb levels decreased in CSF in an
age-dependent manner (Fig. 2A) and the cause is likely to
be different from that decreasing the Ab level in CSF
(Fig. 2B). Thus, we explored the protein levels of Alcb
and the APP in the monkey brain. The Alcb levels in the
brain significantly decreased with age, although some indi-
vidual differences are observed. In contrast to this, age-
related decrease in the APP level was not significant
(Fig. 3). The decrease in the p3-Alcb level in CSF may be
due to the remarkable decrease of Alcb expression in neu-
rons, and again, the decrease of Ab level in CSF is largely
caused by brain accumulation [31,34].
3.4. Human CSF p3-Alcb37 and p3-Alcb40 levels in
patients with AD, patients with MCI, and non-AD subjects
We next examined p3-Alcb levels in CSF of patients with
AD because levels of p3-Alca species changed in CSF and
plasma of patients with AD [22,26–28,35]. Subject data in-
formation of the three cohorts is summarized (Table 1), and
the p3-Alcb37 and p3-Alcb40 levels were quantified in the
CSF of patients with mild cognitive impairment (MCI) and
AD along with age-matched controls (Supplementary
Table 1). The p3-Alcb37 and p3-Alcb40 levels in respective
three cohorts were combined and compared among control
non-AD, MCI and AD subjects (Fig. 4). The p3-Alcb37
levels were found to be significantly lower in patients with
AD than those of control subjects (Fig. 4A). The p3-
Alcb40 levels of patients with AD were again significantly
lower than those of control subjects, whereas the levels in
MCI subjects were not significant to control subjects. How-
ever, p3-Alcb40 levels in patients with AD significantly
decreased further compared with those in MCI subjects
(Fig. 4B). Overall, patients with AD showed a significant
decrease in levels of p3-Alcb compared with controls and
showed a further decrease in the levels of p3-Alcb compared
with MCI subjects, at least significantly in p3-Alcb40.
Because CSF Ab42 levels are lower in patients with AD
because of Ab42 aggregation and precipitation in the brain
[36], we measured Ab42 levels in the same 3 cohort samples
(Supplementary Table 2). Because cohort 3 samples were
examined twice using different procedures, results are
shown as cohort 3a and cohort 3b, respectively, in
Supplementary Table 2. CSFAb42 levels were significantly
A
B
Fig. 2. Age-dependent changes in p3-Alcb and Ab levels in CSF of cynomolgusmonkeys. (A) Correlation of p3-Alcb37 (left) and p3-Alcb40 (right) levels with
age. CSF was collected from cynomolgus monkeys of the indicated ages, and the levels of p3-Alcb were quantified using the sELISA described in Fig. 1.(B)
Correlation of Ab40 (left) and Ab42 (right) levels with age. The same CSF samples used in (A) were assayed for levels of Ab40 and Ab42 by sELISA. p3-Alcb
and Ab values are plotted versus age (y, years old). Analysis was performed using Pearson’s correction (n5 15). R2 and significance with P value are indicated.
Abbreviations: Alcb, Alcadein b; CSF, cerebrospinal fluid; sELISA, sandwich enzyme-linked immunosorbent assay; Ab, amyloid b.
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lower in patients with AD and MCI than those in controls, in
all three cohorts. CSF levels of total tau in cohort 1 and
cohort 3a were significantly higher in patients with AD
than those in controls. Likewise, tau levels tended to be
elevated in patients with MCI. Levels of ptau were also
higher in patients with AD and/or MCI than those in controls
in cohort 2 and cohort 3b. Taken together, the p3-Alcb levels
were largely lower in patients with AD than those in age-
matched control subjects, there were also significantly lower
Ab42 levels and higher tau and ptau levels in CSF, which are
characteristic features of AD subjects.
3.5. Decreases in CSF p3-Alcb37 levels in the subjects
carrying familial AD–linked PSEN gene mutations
To examine whether the change of p3-Alcb levels in the
CSF of patients with AD is due to the alteration of g-secre-
tase activity, we quantified the p3-Alcb levels of subjects
who carry PSEN1 gene mutations (Fig. 4C). Given the
limited amounts and numbers of samples, we only examined
p3-Alcb37 levels. p3-Alcb37 levels in the CSF of PSEN1
gene mutation carriers (n 5 9) (H163R, S169L, Q222H,
M233T, S290C) were compared with p3-Alcb37 levels in
the CSF of noncarrier subjects from the same families
(n5 16), as well as subjects who carry APP gene mutations
(n 5 7) (E963Q and V717L) (Fig. 4C). Although it is diffi-
cult to compare these in same age subjects, and Ab levels
were not measured, the CSF from PSEN1 gene mutation car-
riers showed significantly reduced p3-Alcb37 levels
compared with the CSF from the noncarrier subjects. A sum-
mary of study subject information is shown (Supplementary
Table 3). Interestingly, seven of nine carrier subjects re-
mained in a nondemented state (CDR 0), suggesting that
the decrease in the CSF p3-Alcb37 level begins at a prodro-
mal stage before MCI. The results suggest that alteration of
g-secretase activity by disease-causative mutations of the
PSEN1 gene also induce further the reduction in p3-
Alcb37 levels in the CSF of individuals in vivo along with
the decrease of Alcb expression.
3.6. Inverse modulation of g-secretase activity decreases
the production of p3-Alcb37 and increases the generation
of Ab42
The decrease in p3-Alcb in the CSF of aged subjects may
be due to a reduction of Alcb protein expression in the brain
(Figs. 2 and 3). However, the alteration of g-secretase activ-
ity is also suggested to decrease p3-Alcb37 (Fig. 4C). In fa-
milial AD (FAD) subjects who carry dominant PSEN1 or
PSEN2 gene mutations, Ab42 generation increases, and
this is accompanied by a decrease in Ab38 generation, which
is due to the impaired peptidase-like activity of g-secretase
[37]. Therefore, impaired or attenuated activity of g-secre-
tase may increase the generation of Ab42 in some patients
with sporadic AD who do not carry FAD-linked PSEN1 or
PSEN2 gene mutations, although the levels of Ab42 in
CSF are lowered because of Ab deposition in the brain.
Such altered g-secretase activity has been observed in spo-
radic cases [22,38] and can be induced in cells by com-
pounds that inversely modulate g-secretase activity [24].
We examined whether impaired or attenuated activity of
g-secretase may be influencing p3-Alcb levels by using the
g-secretase modulator Aftin-5, which increases Ab42 gener-
ation and to lower generation of Ab38 [39]. Other studies
A
B
C
Fig. 3. Age-dependent changes of Alcb and APP expression in the monkey
brain.(A) Protein levels of Alcb and the APP in the temporal cortices of
various aged cynomolgus monkeys. Brain lysates (10 mg protein) were
analyzed by immunoblotting with anti-Alcb and anti-APP antibodies, along
with the anti–flotillin-1 antibody. (B, C) Band densities of Alcb and APP
were quantified and normalized against the amount of flotillin-1. Relative
ratios for Alcb (B) and APP (C) were plotted versus age. Open symbols indi-
cate samples shown in panel (A). Statistical analysis was performed using
Pearson’s correction, and significance with P-value is indicated. Age (y) in-
dicates years old. Abbreviations: APP, amyloid b protein precursor; Alcb,
Alcadein b.
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have shown an identical trend in p3-Alca generation: it in-
creases p3-Alca38 generation while decreasing that of p3-
Alca35 [24]. HEK293 cells stably expressing APP CTF or
Alcb CTF were treated with Aftin-5, and secreted Ab and
p3-Alcb were quantified (Fig. 5). Aftin-5 significantly
increased the generation of Ab42 in dose-dependent manner,
along with a modest increase (twofold) in Ab40 (Fig. 5B).
The p3-Alcb37 production decreased significantly by
~20%, whereas p3-Alcb40 production increased twofold,
similar to that of Ab40 (Fig. 5A). The increase in Ab42
and the decrease in p3-Alcb37 generation by Aftin-5 treat-
ment of cells are remarkable. This study suggests that the
greater decrease in p3-Alcb37 levels seen in the CSF of pa-
tients with AD may be due to altered activity of g-secretase
in the AD brain, along with the reduction of Alcb expression
with age. The AD brain may include some alterations which
affect in substrate cleavage by g-secretase, although we
could not examine g-secretase activity of human subjects.
In this cell study, the p3-Alcb40 production increased
twofold with an altered g-secretase activity (Fig. 5A),
whereas the levels in the CSF significantly decreased in pa-
tients with AD (Fig. 4B). In cultured cells, p3-Alcb40 is
not a minor species compared with p3-Alcb37, whereas
p3-Alcb37 is greatly major in the CSF in which the p3-
Alcb37 accounts for 80-90% of the total amounts of p3-
Alcb in CSF [21] (Figs 2A and 4). The small increase of
p3-Alcb40 production in patients with AD may not
contribute for the increase of p3-Alcb40 level in aged pa-
tients with AD. Furthermore, we cannot rule out other possi-
bilities such as a case that patients with AD may further
attenuate the expression of the precursor protein Alcb.
Nevertheless, the cell study, along with the Dominantly In-
herited Alzheimer Network study (Fig. 4C), supports that
the further decrease of p3-Alcb in the CSF of patients with
AD may be due to the altered g-secretase activity in the
brain.
4. Discussion
The proteolytic cleavages of the Alc family proteins
result in the secretion of p3-Alc peptides into cell media or
CSF [2,20,21]. The p3-Alc peptides do not aggregate, which
is quite different from Ab, for which the longer peptides
readily form oligomers, amyloid fibrils, and plaques by ag-
gregation and precipitation.
A
C
B
Fig. 4. Comparisons of the p3-Alcb levels in the CSF of patients with sporadic AD, patients with MCI, and nondemented subjects, and in the CSF between
subjects with or without PSEN gene mutations. CSF p3-Alcb37 (A) and p3-Alcb40 (B) levels were compared among non-AD controls (n 5 117), patients
with MCI (n 5 44) and patients with AD (n 5 76) subjects. The summary of subjects and results is shown in Tables 1, and Supplementary Tables 1 and 2.
Statistical examination was performed with the Kruskal-Wallis test, and P-values are indicated (*P , .05; ***P , .001). (C) p3-Alcb37 levels in CSF were
compared between subjects with PSEN1 mutations (carrier, n 5 9, closed square) and those without PSEN1 mutations (noncarrier, n 5 23). The summary
of subjects is shown in Supplementary Table 3. Noncarriers (average age 42) include family members of carriers (n5 16, closed circle) and subjects carrying
APP gene mutation (n5 7, open circle). Statistical examination was performed byMann-Whitney U test, and P-values are shown (*P5 .0361). Carriers include
seven nondemented (CDR 0) subjects, whereas noncarriers include 19 nondemented (CDR 0) subjects. Error bars indicate6 S.E. Abbreviations: Alcb, Alcadein
b; AD, Alzheimer’s disease; CSF, cerebrospinal fluid; MCI, mild cognitive impairment; APP, amyloid b protein precursor; CDR, clinical dementia rating; S.E.,
standard error.
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Presenilin is a catalytic component of g-secretase com-
plex, and the cleavage of Alc CTF by g-secretase is altered
by FAD-linked PSEN gene mutations, as with APP CTF.
However, the magnitude of the changes caused by these al-
terations in g-cleavage of Alca, Alcb, Alcg and APP CTFs
are not equivalent. The sensitivity of these different proteins
to altered g-secretase activity, which may be observed in
some AD patients, can indeed vary considerably [21,22].
Thus, quantitative and qualitative changes in p3-Alc and
Ab in CSF may be a useful indicator to explore the alter-
ations in substrate cleavage by g-secretase in AD and/or pro-
dromal subjects, whereas investigating qualitative and
quantitative changes in Ab levels in CSF is almost impos-
sible because of the peptide’s propensity to aggregate.
So far, systems to quantify p3-Alcb37 and p3-Alcb40 had
not been developed, and changes in p3-Alcb levels in pa-
tients with AD and in aged subjects remained to be investi-
gated. In the present study, we developed new sELISA
systems and found that levels of p3-Alcb37 and p3-
Alcb40 decreased remarkably in an age-dependent manner
in monkey CSF, and the decrease in p3-Alcb levels may
be due to an attenuated expression of Alcb.
In the analysis of p3-Alcb levels in the CSF of human sub-
jects, a significant decrease in CSF p3-Alcb37 and p3-Alcb40
levels were detected in patients with AD compared those of
age-matched controls. As seen in previous studies, Ab42
levels were significantly lower in the CSF of patients with
MCI and AD [36]. Furthermore, other “gold standard” AD
biomarkers such as ptau181 or total tau levels also increased
in patients with MCI and/or AD in the three cohorts. Taken
together, the results show that there is a decrease in both
p3-Alcb37 and p3-Alcb40 levels in the CSF of subjects
who altered the levels of other AD biomarkers.
Our comparisons of AD, MCI, and control CSF revealed
that patients with AD and patients with MCI had lower p3-
Alcb levels in their CSF than age-matched controls. Results
were statistically significant between non-AD controls and
AD. We propose a hypothesis that a significantly decreased
p3-Alcb, especially p3-Alcb37, level in a subject may suggest
some alteration of g-secretase activity in the AD brain, which
may also indicate increased neurotoxic Ab42 generation in
the brain. Although we did not have the direct evidence to
show altered g-secretase activity in the AD brain, a cell study
with g-secretase modulator Affitin-5 and the p3-Alcb37 value
in CSF of FAD carrier may support the idea.
We propose here that the rise of the Ab amounts and the
set of p3-Alcb levels in the brain may contribute to neuronal
impairment in AD. Indeed, our separate study indicates that
p3-Alcb provides protection against the neuronal toxicity
induced by Ab42 oligomers (Hata et al., in preparation).
A
B
Fig. 5. Altered generation of p3-Alcb and Ab species in HEK293 cells after treatment with g-secretase inverse modulator Afitin-5.(A) Effect of Afitin-5 in p3-
Alcb generation. HEK293 cells transiently expressing Alcb CTF were treated with or without the indicated amount of Afitin-5 for 24 h. The amounts of p3-
Alcb37 and p3-Alcb40 in conditioned mediumwere quantified (pg/mL) by sELISA as described in Fig. 1. (B) Effect of Afitin-5 in Ab generation. HEK293 cells
transiently expressing APP CTF were treated with or without the indicated amount of Afitin-5 for 24 h. The amounts of Ab40 and Ab42 in conditioned medium
were quantified (pg/mL) by sELISA. Error bars indicate 6 S.E. (n 5 3). Statistical analysis was performed using Dunnett’s test, and P-values are indicated
(**P, .01; ***P, .001). Abbreviations: Alcb, Alcadein b; CTF, carboxyl-terminal fragments; Ab, amyloid b; APP, amyoid b protein precursor; S.E., standard
error.
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We have noted the CSF p3-Alcb levels
significantly decrease in patients with AD compared with
those in age-matched controls. Moreover, a cell study found
that the g-secretase modulator Aftin-5 caused a decrease in
p3-Alcb37 generation along with a concomitant increase in
the generation of Ab42 (Fig. 5). These observations also sug-
gest that a decrease in p3-Alcb in vivo may be an indicator
for increased Ab42 production in the brain; thus, it is
possible that decreases in p3-Alcb in the central nervous sys-
tem may facilitate the neuronal toxicity by increased Ab42
in the brain. This hypothesis may be supported with our anal-
ysis that CSF from subjects who have autosomal dominantly
inherited AD due to PSEN gene mutations show reduced p3-
Alcb37 levels at a young age of 30 years, compared with that
from subjects who do not carry PSEN gene mutations at the
age of 40. We expect that age-associated decreases in p3-
Alcb levels in CSF and the time at which Ab accumulation
in the brain increases dramatically with age may be indica-
tive of the time of developing cognitive impairment. This
point may be the starting point to care neuronal and/or
cognitive impairment. Although we need to carry out further
analysis concerning the potential neuroprotective function
of p3-Alcb in vivo, expanding our concurrent study has re-
vealed that p3-Alcb preserves neurons from the toxicity of
Ab42 oligomers. Exactly, we have found that a shorter pep-
tide, part of p3-Alcb37, is the druggable seed with a novel
target to care neurotoxicity induced by Ab42 oligomer
(see Research in Context). Therefore, studies for metabolism
and function of p3-Alcb may lead to a novel-drug develop-
ment to prevent or slow AD pathogenesis.
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RESEARCH IN CONTEXT
1. Systematic review: We first delivered a short state-
ment for the value of p3-Alcb peptide quantifica-
tion. The p3-Alcb peptides are generated from the
neuron-specific precursor protein Alcadein b
(Alcb) through cleavage by a- and g-secretases
similar to the amyloid b protein precursor (APP).
As with Ab, secreted p3-Alcb is detectable in ce-
rebrospinal fluid (CSF), and shows non–aggrega-
tion-prone properties. Therefore, changes of CSF
p3-Alcb levels in quality and in quantity reflect the
alteration of g-secretase activity in the brain. We
developed new sandwich enzyme-linked immuno-
sorbent assay (sELISA) systems to quantitate CSF
levels of p3-Alcb. Using the new tools, we found
that CSF p3-Alcb decreases with age, and the aging
is also accompanied by decreased brain expression
of Alcb (monkeys). Moreover, we found that CSF
p3-Alcb levels decrease to a greater extent in pa-
tients with AD than those in age-matched controls.
We also found that subjects carrying presenilin
gene mutations show a significantly lower CSF p3-
Alcb level. These observations suggest that p3-
Alcb decrease with age by lowered expression of
Alcb precursor protein. Furthermore, the observa-
tions suggest that the g-secretase activity may be
altered/attenuated in AD brains compared with that
in age-matched controls. Although it is very diffi-
cult to demonstrate the alteration of g-secretase
activity in the AD brain, we partially showed that
alteration of g-secretase activity decreases p3-
Alcb37 along with the increase of Ab42 genera-
tion by cell study.
2. Interpretation: In this article, we do not describe the
physiological function of p3-Alcb peptide in vivo
and in vitro. Nevertheless, we would like to hy-
pothesize that the decrease of p3-Alcb production in
the central nervous system may facilitate the neuro-
toxicity induced by increasing Ab42 oligomers with
age. Because we have found that p3-Alcb suppressed
neurotoxicity induced by Ab42 oligomers (results
are partially described in US patent https://patent-
s.google.com/patent/US10206979B2/en, and whole
results are in preparation for publication), we believe
that p3-Alcb plays an important role in the
enhancement of neuronal viability. We also propose
that age-associated decreases in p3-Alcb levels in
CSF and the time at which Ab accumulation in the
brain increases dramatically with age may be indic-
ative of the time of developing cognitive impairment.
This point may be the starting point to care neuronal
and/or cognitive impairment.
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3. Future directions: Currently, we have analyzed the
molecular function of p3-Alcb peptide to preserve
neurons. We found that a partial peptide has an
ability to counteract neurotoxicity induced by Ab42
oligomers (https://patents.google.com/patent/
US10206979B2/en). Therefore, we expect that the
drug development based on p3-Alcb peptide may be
innovative to prevent or slow AD pathogenesis with
novel therapeutic effects.
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